Incyte (INCY) sees Phase 3 success for vitiligo drug povorcitinib, yet trails AbbVie (ABBV) Rinvoq
Clinical Phase 3 Success of Oral Vitiligo Treatment Candidate
Incyte (INCY) is developing an oral JAK1 selective inhibitor called povorcitinib. In the Phase 3 trials STOP‑V1 and STOP‑V2 in nonsegmental vitiligo patients, the primary endpoint was successfully met. In these late‑stage studies, 18.9% of patients receiving povorcitinib 30 mg achieved ≥75% improvement in facial vitiligo area score (F‑VASI75) at week 52, versus 6.8% in the placebo arm of STOP‑V1 and 3.1% in STOP‑V2, demonstrating a statistically significant pigment‑restoration effect. The data establish povorcitinib as a potent systemic therapy that can markedly reduce the aesthetic and psychosocial burden experienced by patients. Based on these positive results, Incyte plans to file a regulatory NDA in the first half of 2027.
Inevitable Efficacy Comparison and Gap with AbbVie Rinvoq
However, Wall Street analysts consider the results somewhat disappointing when benchmarked against market leader AbbVie (ABBV)’s Rinvoq (upadacitinib). AbbVie released topline Phase 3 data for Rinvoq in vitiligo in October 2025, showing a placebo‑adjusted benefit of 17%–19%. In contrast, povorcitinib’s placebo‑adjusted improvement was 12.1% in STOP‑V1 and 15.8% in STOP‑V2, falling short of Rinvoq’s figures. Given that even modest efficacy differences among oral JAK inhibitors drive prescribing preferences, the commercial competitiveness of povorcitinib is called into question.
Shifting Competitive Landscape in the Vitiligo Treatment Market and First‑Mover Advantage
The global vitiligo market is estimated at $1.43 billion–$1.84 billion in 2025 and is projected to reach up to $2.91 billion in the early 2030s, representing a high‑growth segment. The market is currently dominated by Incyte’s topical formulation Opzelura (ruxolitinib), approved in July 2022, while demand for systemic oral therapy for patients with extensive disease remains strong. AbbVie has already submitted FDA and EMA applications for Rinvoq’s vitiligo indication, positioning it to claim the title of the first systemic oral treatment. For Incyte, the later submission timeline and lack of clear clinical superiority create a substantial marketing barrier to early market entry.
Diversification Strategy for the Povorcitinib Pipeline and Impact on Corporate Value
Although povorcitinib did not outpace AbbVie in the vitiligo indication, Incyte remains committed to developing it as a core asset within a diversified immune‑mediated dermatology pipeline. Povorcitinib is being pursued for hidradenitis suppurativa, with planned FDA and EMA submissions in Q1 2027 and late 2026, respectively, and Phase 3 data for prurigo nodularis are expected in Q4 2026. Additionally, Phase 2 results for an asthma indication are slated for H2 2026. If these programs progress on schedule, they could offset the setback in vitiligo. Investors are closely monitoring whether rapid commercialization in other unmet medical need markets can compensate for the relative weakness in vitiligo.
Incyte’s oral JAK1 inhibitor povorcitinib demonstrated efficacy in a Phase 3 vitiligo trial, but its placebo‑adjusted benefit (12.1%–15.8%) fell short of AbbVie’s Rinvoq (17%–19%), diminishing its commercial appeal as a later entrant. AbbVie completed its trial in October 2025 and has already filed for FDA and EMA approval, whereas Incyte will not be able to submit until the first half of 2027, creating at least a one‑year first‑to‑market gap. In a global vitiligo market valued at $1.43 billion–$1.84 billion in 2025, the systemic oral segment is likely to be dominated by Rinvoq while the topical segment remains split with Incyte’s existing product Opzelura, risking an entrenched market division. From the perspective of researchers and industry professionals, even subtle efficacy differences arising from drug delivery modality and molecular selectivity within the same JAK1 target can be decisive factors for regulatory approval and prescribing patterns. Consequently, Rinvoq is expected to enjoy short‑term market dominance, but the medium‑to‑long‑term recovery of Incyte’s valuation will hinge on whether povorcitinib can preserve pipeline value through expansion into other indications such as hidradenitis suppurativa (submission anticipated late 2026).